Kogenate treatment of previously untreated patients (PUPs) with hemophilia A: Update of safety, efficacy, and inhibitor development after seven study years.

被引：0

作者：

Lusher, J

Arkin, S

Abildgaard, CF

Hurst, D

机构：

[1] MT SINAI SCH MED,NEW YORK,NY

[2] WAYNE STATE UNIV,DETROIT,MI

[3] BAYER CORP,BERKELEY,CA

[4] UNIV CALIF DAVIS,SACRAMENTO,CA 95817

来源：

BLOOD | 1996年 / 88卷 / 10期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1755 / 1755

页数：1

共 50 条

[31] A MULTICENTER STUDY OF RECOMBINANT FACTOR-VIII (RECOMBINATE) - SAFETY, EFFICACY, AND INHIBITOR RISK IN PREVIOUSLY UNTREATED PATIENTS WITH HEMOPHILIA-A
BRAY, GL
GOMPERTS, ED
COURTER, S
GRUPPO, R
GORDON, EM
MANCOJOHNSON, M
SHAPIRO, A
SCHEIBEL, E
WHITE, G
LEE, M
GORDON, M
BERTALONE, S
LIPTON, R
HILGARTNER, M
ARKIN, S
GILL, J
KIM, H
SHURIN, S
SANTIAGOBORRERO, P
ARKEL, YS
KULKARNI, R
GREENWOOD, MF
RITCHEY, AK
WERNER, E
HAIRE, WD
KISKER, T
NEUFELD, E
EWENSTEIN, B
DEBIASI, R
LAURIAN, Y
KREUZ, W
RODEGHIERO, F
INGERSLEV, J
GAZENGEL, C
DIMICHELE, D
COOPER, H
BLOOD, 1994, 83 (09) : 2428 - 2435
[32] Systematic Review of the Role of FVIII Concentrates in Inhibitor Development in Previously Untreated Patients with Severe Hemophilia A: A 2013 Update
Franchini, Massimo
Coppola, Antonio
Rocino, Angiola
Santagostino, Elena
Tagliaferri, Annarita
Zanon, Ezio
Morfini, Massimo
SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2013, 39 (07): : 752 - 766
[33] A clinical study in previously untreated patients with severe hemophilia A - Immunogenicity, efficacy and safety of treatment with human-cl rhFVIII
Liesner, Raina
Jansen, Martina
Knaub, Sigurd
HAEMOPHILIA, 2014, 20 : 17 - 17
[34] Inhibitor development, safety, and efficacy of Advate® in previously untreated patients with hemophilia A in a postmarketing surveillance in Japan (vol 109, pg 70, 2019)
Taki, Masashi
Fukutake, Katsuyuki
Matsushita, Tadashi
Nogami, Keiji
Shima, Midori
Yoshioka, Akira
Takamatsu, Junki
Arai, Morio
Takagi, Hiroshi
Uchikawa, Haruhiko
Engl, Werner
Shirahata, Akira
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2019, 109 (02) : 241 - 241
[35] Factor VIII prophylaxis and inhibitor development in previously untreated patients with severe hemophilia A: the RODIN study
Gouw, S. C.
Van den Berg, M.
Auerswald, G.
Carcao, M.
Chalmers, E.
Chambost, H.
Fischer, K.
Kurnik, K.
Liesner, R.
Petrini, P.
Platokouki, H.
Altisent, C.
Oldenburg, J.
Nolan, B.
Perez Garido, R.
Rafowicz, A.
Williams, M.
Van der Bom, J. G.
HAEMOPHILIA, 2012, 18 : 3 - 4
[36] Guardian™ 4: safety and efficacy of turoctocog alfa in prevention and treatment of bleeds in previously untreated patients with hemophilia A
Ozelo, M.
Wu, R.
Belhani, M.
Lebedev, V.
Yaish, H.
Korsholm, L.
Matytsina, I.
Matsushita, T.
HAEMOPHILIA, 2018, 24 : 101 - 102
[37] Factor VIII prophylaxis and inhibitor development in previously untreated patients with severe hemophilia A: The RODIN study
Gouw, S.
Van den Berg, H.
Van der Bom, J.
HAEMOPHILIA, 2012, 18 : 89 - 89
[38] Transcriptomic Profiling to Understand Inhibitor Development in Previously Untreated Patients with Severe Hemophilia a
Batty, Paul
Watson, David
Wozniak, Eva
Mein, Charles
Barnes, Michael
BLOOD, 2023, 142
[39] Inhibitors in previously untreated patients (PUPS) with severe hemophilia A: a follow-up cohort study
Mancuso, M. E.
van den Berg, H. M.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 : 846 - 846
[40] Exploration of biomarkers for early recognition of FVIII inhibitor development in previously untreated severe hemophilia A patients: Hemophilia Inhibitor PUP Study and beyond
Hofbauer, C. J.
Male, C.
Brown, D.
Santagostino, E.
Oldenburg, J.
Scheiflinger, F.
Reipert, B. M.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2013, 11 : 133 - 133

← 1 2 3 4 5 →